Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion. - Wikidata - wikimedia - TriplyDB

Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.

Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.

http://www.wikidata.org/entity/Q37716485

about

RNA sequencing of esophageal adenocarcinomas identifies novel fusion transcripts, including NPC1-MELK, arising from a complex chromosomal rearrangement.Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer.MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines.

P2860

Q38714000-BBD57ABB-C6FB-4CCC-B78B-38E0FE8EB5A5 Q44643445-9294EF88-CC98-4DEA-8809-A1798D0B5589 Q47106713-B6D45553-8D7D-420C-B75D-4B38C9780FD3

P2860

Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.

http://www.wikidata.org/entity/Q37716485

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 January 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Acquired resistance to LY28744 ...... e of novel FGFR2-ACSL5 fusion.

@en

Acquired resistance to LY28744 ...... e of novel FGFR2-ACSL5 fusion.

@nl

type

label

Acquired resistance to LY28744 ...... e of novel FGFR2-ACSL5 fusion.

@en

Acquired resistance to LY28744 ...... e of novel FGFR2-ACSL5 fusion.

@nl

prefLabel

Acquired resistance to LY28744 ...... e of novel FGFR2-ACSL5 fusion.

@en

Acquired resistance to LY28744 ...... e of novel FGFR2-ACSL5 fusion.

@nl

P1433

Q37716485-0F2B6ACB-B4AD-4771-85C2-F09AACB74AA6

P1476

Q37716485-9C87B1F2-0BD0-4364-891E-0D612D8D78FF

P2093

Q37716485-167D9E28-C386-4691-BB77-54624777B204

Q37716485-2581BF0B-29D2-43CD-A17E-42065A6F03D4

Q37716485-3848E545-2697-46B0-A367-CEAEFE44F518

Q37716485-5207E39C-2CA8-4E1E-8BCB-DC808D0F1D1E

Q37716485-812587D5-401F-4D3B-BD81-F6BDA6C81E78

Q37716485-8309326B-1B2D-4096-8A3A-2170FD9F831F

Q37716485-87038D53-1C6D-4B13-898D-475EC0769176

Q37716485-9B69A9C7-B699-4100-B41C-FA66C5E7401C

Q37716485-9F72D4CB-BEBF-41C8-9D7C-81E7B8C9EC62

Q37716485-A4D6D99A-36C4-436F-88C2-FA5189BEAAA1

P2860

Q37716485-100A91B7-E207-4B18-AB23-C1C36EE0AC90

Q37716485-13602E50-F4E9-42DC-B0F1-E8A79CF95FFF

Q37716485-189A518C-5C54-43B6-888D-38A5D9376FAF

Q37716485-1EA699D8-BEEB-4E09-9D29-3B00B7A1FBF4

Q37716485-43E816F7-74A3-468B-9188-4E3678357A8E

Q37716485-497D32E6-B5A1-4D13-8146-E0AB2595AF32

Q37716485-4AEED5CA-F0DE-4A14-A492-3218F121A3E3

Q37716485-615A7E57-A6F2-49DA-925C-119BB5A36E98

Q37716485-63F60B17-EE3C-4063-8D30-0A105147F1DD

Q37716485-746B72AB-5210-4A0B-946A-6E3641CD2201

P304

Q37716485-10D1BD2E-1C57-4D6D-BEDE-B281E5C04F4D

P31

Q37716485-5E304370-48E3-410D-B010-7320DB0C7D8B

P356

Q37716485-F3D8A318-AFCF-468F-AAB9-1E34CD05D96E

P407

Q37716485-1A2C045D-98A8-47C2-B7E1-E4CDD1597DAB

P433

Q37716485-84B69207-BAFE-4BB3-83F0-669116925B7A

P478

Q37716485-893B745F-56C0-4D0A-8830-D4DF34F279FF

P577

Q37716485-C97563E4-B035-4AF2-ACC3-67031B0E3492

P698

Q37716485-69B07A58-B8BF-42F2-A2D4-64C00368EB8B

P932

Q37716485-306F1221-D898-4921-84DD-A895C566C8A1

P356

ONCOTARGET.14788

P1433

P1476

Acquired resistance to LY28744 ...... e of novel FGFR2-ACSL5 fusion.

@en

P2093

Byung Hoon Min

http://www.w3.org/2001/XMLSchema#string

Heejin Bang

http://www.w3.org/2001/XMLSchema#string

Hyuk Lee

http://www.w3.org/2001/XMLSchema#string

Jeeyun Lee

http://www.w3.org/2001/XMLSchema#string

Jiryeon Jang

http://www.w3.org/2001/XMLSchema#string

Jun Soo Ham

http://www.w3.org/2001/XMLSchema#string

Jusun Kim

http://www.w3.org/2001/XMLSchema#string

Kyoung-Mee Kim

http://www.w3.org/2001/XMLSchema#string

Moonhee Shim

http://www.w3.org/2001/XMLSchema#string

Se Hoon Park

http://www.w3.org/2001/XMLSchema#string

P2860

Ultrafast and memory-efficient alignment of short DNA sequences to the human genome

Adjusting batch effects in microarray expression data using empirical Bayes methods

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Personalized identification of altered pathways in cancer using accumulated normal tissue data.

Analysis of RNA-Seq data with TopHat and Cufflinks for genome-wide expression analysis of jasmonate-treated plants and plant cultures.

Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth.

The landscape of kinase fusions in cancer

Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.

Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.

P304

15014-15022

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.14788

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28122360

http://www.w3.org/2001/XMLSchema#string

P932

5362463

http://www.w3.org/2001/XMLSchema#string